Articles On Noxopharm (ASX:NOX)

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Noxopharm (ASX: NOX) is the latest small cap to reveal it has a potential COVID-19 treatment, after it reported this morning its advanced idronoxil drug could block an excessive inflammatory response believed to be responsible for many COVI...

Australian clinical stage drug development company Noxopharm Limited (ASX:NOX) recently announced a significant milestone, that its potentially transformative anti-cancer drug candidate Veyonda® has been awarded first allowed patent applica...

Noxopharm (ASX:NOX) has announced that the last patient has been enrolled and safely dosed in the ongoing LuPIN Phase 1/2 clinical trial being conducted by St Vincent’s Hospital Sydney.

CEO Graham Kelly PhD said, “Bringing Veyonda to market for late-stage prostate cancer remains our commercial imperative. This IND grant for a less common cancer type contributes to that overall commercial objective in several ways."...

Mirroring the wider market, many of the small cap IPOs completed so far in 2020 have white-knuckled their way through the opening months of the new decade. Only two – COSOL and Cobre – made solid gains. The rest bounced around like a House...

Latest LuPIN Trial Interim Results and an Alliance with Oncology Services Provider, GenesisCare Further Enhance Veyonda®’s Potential Commercial and Shareholder Value  Australian clinical-stage drug development company Noxopharm Limite...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Noxopharm (ASX:NOX) has announced a new clinical alliance with oncology services provider GenesisCare to offer a compassionate access program with its novel lead product candidate, Veyonda.

Nyrada was established in 2017 to advance the non-oncology assets developed by Noxopharm, leaving Noxopharm free to concentrate on the development of Veyonda.

Sydney biotech company Nyrada has made its debut on the ASX in the first float of the year following an $8.5 million initial public offering.

It was a solid debut for drug manufacturer Nyrada (ASX:NYR) on the ASX this morning. Nyrada raised $8.5m and opened its first session 52.5 per cent higher than its 20c IPO price, hitting an early peak of 30.5c.   Nyrada is a spin off of f...

Following an oversubscribed IPO, Noxopharm’s (NOX) U.S. spin-off Nyrada has listed on the ASX under the code NYR Post-listing, Noxopharm will hold an almost 27 per cent shareholding in Nyrada Nyrada was established in 2017 to help Noxoph...

Australian biotech Noxopharm’s (ASX: NOX) US spin-off Nyrada Inc experienced strong demand in its initial public offering and will now make its ASX debut today after successfully raising $8.5 million under the ticker ‘NYR’. Nyrada was estab...

20 Dec 2019 - Clinical drug development company Noxopharm (ASX:NOX) has released DARRT-1 study clinical data which it says shows strong anti-cancer response in 47% of men with late…

The Boards of Noxopharm (NOX) and Nyrada have received full commitments for the $8.5 million IPO Noxopharm was advised by Lead Manager, Alto Capital that the IPO has been fully allocated and reconciliation of funds are underway Nyrada i...

Antisense Therapeutics (ASX:ANP) jumped over 20 per cent this morning on news its ATL1102 drug, fighting Duchenne Muscular Dystrophy (DMD), delivered strong preliminary results in its clinical trial. The stock is now up 270 per cent over th...

Australian drug development company, Noxopharm Limited (ASX: NOX) recently announced the completion of DARRT-1 Phase 1b study in late-stage prostate cancer, reporting  positive end-of-study data. Following that announcement, NOX shares rose...

Noxopharm Ltd (ASX: NOX), a clinical-stage Australian drug development company, has secured an increase to its existing funding agreement with two New York institutional investors– Lind Global Macro Fund, LP and CST Investment Fund. The ag...

Australian company Noxopharm (ASX:NOX) has reported positive end-of-study data from its DARRT-1 Phase 1b trial of Veyonda.

Biotech drug developer Noxopharm (ASX: NOX) has reported positive end-of-study results from its DARRT-1 Phase 1b trial treating men with late-stage prostate cancer. In an update yesterday, the oncology-focused company announced that clinica...

Australia headquartered clinical stage drug development company, Noxopharm Limited (ASX: NOX) has been in the spotlight for its potentially transformative therapy in late-stage prostate cancer where few or no standard therapy exists current...

Emerging Australian oncology company Noxopharm (ASX:NOX) has used its annual general meeting to update investors on its pipeline.

Clinical-stage drug development company, Noxopharm Limited (ASX: NOX) continues to show  its potentially transformative therapy in late-stage prostate cancer where few or no remaining standard treatment options currently exist. Noxopharm’s...

The company said Mr Hunter’s skills will add important management strength to its executive team as it embarks on its next phase of growth.

Noxopharm Limited (ASX: NOX) has recently provided an update related to the research progress on its key drug candidate Veyonda® which is presently undergoing clinical trials in late-stage, progressive and metastatic, castration-resistant p...

The TechKnow Invest Roadshow provides retail and institutional investors, as well as brokers, an opportunity to learn more about a range of tech and biotech companies. More than 20 companies will present at the conference on Thursday, Octob...

Sydney-based Noxopharm (ASX:NOX) has updated on interim data from the DARRT-1 study where Veyonda is being tested in patients with prostate cancer which is late-stage, progressive and metastatic.

Drug development company Noxopharm (ASX: NOX) is growing more optimistic about the use of its Veyonda treatment on patients with late-stage prostate cancer. NOX provided an interim update on its DARRT-1 clinical trial, where patients are gi...

Anti-cancer drug developer Noxopharm (ASX: NOX) has set the stage to present its highly-anticipated clinical data to the Clinical Oncology Society of Australia by publishing interim data from a DARRT-1 clinical study using Veyonda to treati...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

16 Oct 2019 - Noxopharm (ASX:NOX) has made some changes to its senior executive and Board structures.

Australian clinical-stage drug development company, Noxopharm Limited (ASX: NOX), has provided commentary on clinical data to be released to a cancer conference in November. Noxopharm believes that the data adds to the growing body of evide...

Noxopharm (ASX:NOX) has provided further information on the upcoming release of clinical data concerning its lead drug candidate, Veyonda, saying it "now sees an important and exciting story emerging".

Noxopharm (ASX: NOX) is in the process of making Veyonda®, which is a drug that boost the effectiveness of two forms of radiation therapy in prostate cancer with the aim of relieving pain, decreasing the activity of the cancer and extending...

Noxopharm (ASX:NOX) has announced that scientific abstracts on interim data relating to its DARRT-1 prostate cancer treatment study have been accepted for inclusion in two major oncology conferences.

Noxopharm Limited is a clinical stage drug development company that is currently investing its lead anti- cancer drug. Join Our Discussion Start discussion with value Investors for ASX Stock Market Investment and Opinion. 6 Cannabis S...

Noxopharm (ASX:NOX) has provided an update on results from a series of proof-of-principle experiments in mice that are exploring the interaction between Veyonda and radiotherapy in a novel treatment regimen known as DARRT.

Noxopharm Limited (ASX: NOX) has recently released its quarterly report for the three months ended 30 June 2019, covering updates from both Noxopharm and its majority-owned subsidiary, Nyrada Inc. Let us travel through the chief development...

Sydney-based company Noxopharm is developing a new approach to cancer treatment that is designed to convert 'cold' tumours to 'hot' so they can be recognised by the immune system.

Noxopharm Limited (ASX: NOX) plans to accelerate the development of Veyonda® on the foundation of its encouraging interim results from both its DARRT-1 and LuPIN studies. The most recent  data supports the company’s belief that its immuno-o...

Medibio (ASX: MEB) has gained 24 per cent this morning after announcing an integration partnership with digital corporate wellness solution WellteQ. Medibio’s “ilumen” digital mental well-being assessment will be integrated into WellteQ’s s...

Noxopharm Limited (ASX: NOX) is a clinical stage drug development company based in Australia. The company, currently, is focused on investigating the potential of its drug candidate Veyonda® with the vision to launch it as a one big solutio...

Noxopharm Limited (ASX: NOX) has released July 2019 edition of its Newsletter called ‘Versatility’. The clinical-stage drug development company, Noxopharm reports on the progress of its lead anti-cancer drug candidate Veyonda® achieved over...

Clinical stage drug development company, Noxopharm Limited (ASX: NOX) aims to bring hope to cancer patients who have reached the end of their treatment journey and have no standard treatment options remaining, except palliative therapy for...

In the world of cancer, one billion-dollar molecule that has been making a big noise for its potential to extend life in men with the late-stage prostate cancer, concerns an experimental radioactive drug called Lutetium-177 (177Lu) labelled...

The big noise internationally in the treatment of prostate cancer is an experimental drug called 177Lu-PSMA-617. It is what is called a radiopharmaceutical, meaning that it is a radioactive drug that is injected intravenously. It is a way o...

Clinical-stage drug development company, Noxopharm Limited (ASX: NOX) has released its updated corporate presentation for June 2019. The company, with offices in Sydney, New York and Hong Kong, is developing its leading drug candidate, Veyo...

07 Jun 2019 - Noxopharm (ASX:NOX) has seen its majority-owned US subsidiary company, Nyrada receive a cash rebate of over $486,000 under the Australian Government’s R&D Tax Incenti…